Drug-induced macular edema

Drugs

Volumn 73, Issue 8, 2013, Pages 789-802

  Makri, Olga E ^a   Georgalas, Ilias ^b   Georgakopoulos, Constantine D ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ADRENALIN; ALPHA INTERFERON; BENZALKONIUM CHLORIDE; BETA INTERFERON; BETAXOLOL; BEVACIZUMAB; BIMATOPROST; DOCETAXEL; ETRETIN; FINGOLIMOD; FLUCONAZOLE; GAMMA INTERFERON; HYDROCHLOROTHIAZIDE; IMATINIB; LATANOPROST; LEFLUNOMIDE; METFORMIN; NICOTINIC ACID; PACLITAXEL; PIOGLITAZONE; RIFABUTIN; RITUXIMAB; ROSIGLITAZONE; TAMOXIFEN; TIMOLOL; TRAVOPROST; UNOPROSTONE; ZIDOVUDINE;

BLOOD EYE BARRIER; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER PREVENTION; CHRONIC MYELOID LEUKEMIA; COCCIDIOIDOMYCOSIS; CONJUNCTIVAL HYPEREMIA; DIABETIC RETINOPATHY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EYE IRRITATION; EYE TOXICITY; FUNGAL MENINGITIS; GLYCEMIC CONTROL; HAIRY CELL LEUKEMIA; HEART VENTRICLE FAILURE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOPYON; INTRACELLULAR FLUID; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; KAPOSI SARCOMA; LOW DRUG DOSE; LUNG EDEMA; LUNG INFECTION; MAXIMUM TOLERATED DOSE; MELANOMA; META ANALYSIS (TOPIC); MICROCIRCULATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NERVE FIBER DEGENERATION; OSMOTIC PRESSURE; PERIPHERAL EDEMA; PHACOEMULSIFICATION; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTORECEPTOR OUTER SEGMENT; PIGMENT EPITHELIUM; PLASMA VOLUME; PSEUDOPHAKIA; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA CYSTOID EDEMA; RETINA MACULOPATHY; RETINAL THICKNESS; RETINITIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; VISUAL ACUITY; VITRITIS; WEGENER GRANULOMATOSIS;

ADRENERGIC BETA-ANTAGONISTS; ANTINEOPLASTIC AGENTS; HUMANS; HYPOLIPIDEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; MACULAR EDEMA; NIACIN; OPHTHALMIC SOLUTIONS; PROPYLENE GLYCOLS; SPHINGOSINE; TAMOXIFEN; TAXOIDS; THIAZOLIDINEDIONES; TIMOLOL;

EID: 84878937040     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0055-x     Document Type: Review

References (146)

1. Lobo C, Bernardes R, Faria de Abreu JR, Cunha-Vaz JG. Novel imaging techniques for diabetic macular edema. Doc Ophthalmol. 1999;97:341-7.
2. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-18.
3. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association. European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
4. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc. 2003;78:1088-91.
5. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy. 2002;22:924-9.
6. Avandia Package Insert (see adverse reactions section). http://medlibrary.org/lib/rx/meds/rosiglitazone-maleate.
7. Actos Package Insert. (see adverse reactions section). http://medlibrary.org/lib/rx/meds/actos/page/6/#-ADVERSE-REACTIONS.
8. Bando Y, Ushiogi Y, Okafuji K, Toya D, Tanaka N, Fujisawa M. Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors. J Int Med Res. 1999;27:53-64.
9. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract. 2003;9:406-16.
10. Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol. 2005;123:1273-5.
11. Ryan EH Jr, Han DP, Ramsay RC, Cantrill HL, Bennett SR, Dev S, Williams DF. Diabetic macular edema associated with glitazone use. Retina. 2006;26:562-70.
12. Emoto M, Anno T, Sato Y, Tanabe K, Okuya S, Tanizawa Y, Matsutani A, Oka Y. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patient and its mRNA in 3T3-L1 adipocytes. Diabetes. 2001;50:1166-70.
13. Oshitari T, Asaumi N, Watanabe M, Kumagai K, Mitamura Y. Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study. Vasc Health Risk Manag. 2008;4:1137-40.
14. Kendall C, Wooltorton E. Rosiglitazone (Avandia) and macular edema. CMAJ. 2006;174:623.
15. Liazos E, Broadbent DM, Beare N, Kumar N. Spontaneous resolution of diabetic macular oedema after discontinuation of thiazolidenediones. Diabet Med. 2008;25:860-2.
16. Asensio-Sánchez VM, Asensio-Sánchez MJ, Gómez-Ramírez V. Macular oedema due to rosiglitazone treatment in diabetes mellitus. Arch Soc Esp Oftalmol. 2010;85:246-8.
17. Tatti P, Arrigoni F, Longobardi A, Costanza F, Di Blasi P, Merante D. Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus. Clin Drug Investig. 2008;28:327-32.
18. Shen LQ, Child A, Weber GM, Folkman J, Aiello LP. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol. 2008;126:793-9.
19. Singh S, Segal JB. Thiazolidinediones and macular edema: comment on "Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes". Arch Intern Med. 2012;172:1011-3.
20. Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol. 2009;147(583-586):e1.
21. Ambrosius WT, Danis RP, Goff DC Jr, Greven CM, Gerstein HC, Cohen RM, Riddle MC, Miller ME, Buse JB, Bonds DE, Peterson KA, Rosenberg YD, Perdue LH, Esser BA, Seaquist LA, Felicetta JV, Chew EY, ACCORD Study Group. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol. 2010;128:312-8.
22. Colucciello M, Ryan E. Macular edema and thiazolidinediones. Arch Ophthalmol. 2010;128:1630-1.
23. Tarbett AK, VanRoekel RC, Howard RS, Vigersky RA. The use of optical coherence tomography to determine the effect of thiazolidinediones on retinal thickness in patients with type 2 diabetes. J Diabetes Sci Technol. 2011;5:945-51.
24. Motola D, Piccinni C, Biagi C, Raschi E, Marra A, Marchesini G, Poluzzi E. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. Drug Saf. 2012;35:315-23.
25. Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med. 2012;172:1005-11.
26. Salvadori M, Budde K, Charpentier B, Klempnauer J, Nashan B, Pallardo LM, Eris J, Schena FP, Eisenberger U, Rostaing L, Hmissi A, Aradhye S, FTY720 0124 Study Group. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transpl. 2006;6:2912-21.
27. Saab G, Almony A, Blinder KJ, Schuessler R, Brennan DC. Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient. Arch Ophthalmol. 2008;126:140-1.
28. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402-15.
29. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401.
30. Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology. 2012;78:672-80.
31. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, Volpi M, Sha'afi RI, Hla T. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell. 1999;99:301-12.
32. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, Bamberg JR, English D. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest. 2001;108:689-701.
33. Tauseef M, Kini V, Knezevic N, Brannan M, Ramchandaran R, Fyrst H, Saba J, Vogel SM, Malik AB, Mehta D. Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1-phosphate receptor signaling in endothelial cells. Circ Res. 2008;103:1164-72.
34. Liu L, Cuthbertson F. Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis. Case Rep Med. 2012;2012:134636.
35. Turaka K, Bryan JS. Does fingolimod in multiple sclerosis patients cause macular edema? J Neurol. 2012;259:386-8.
36. Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA. Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci. 2012;323:167-72.
37. Gilenya medication guide - Food and Drug Administration. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM227569.pdf. Accessed 14 Dec 2012.
38. Eisner A, Luoh SW. Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res. 2011;36:867-85.
39. Teitelbaum BA, Tresley DJ. Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci. 2003;80:277-9.
40. Telander DG, Sarraf D. Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol. 2007;22:151-3.
41. Joshi MM, Garretson BR. Paclitaxel maculopathy. Arch Ophthalmol. 2007;125:709-10.
42. Smith SV, Benz MS, Brown DM. Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol. 2008;126:1605-6.
43. Murphy CG, Walsh JB, Hudis CA, Lake D, Theodoulou M. Cystoid macular edema secondary to nab-paclitaxel therapy. J Clin Oncol. 2010;28:e684-7.
44. Baskin DE, Garg SJ. Abraxane-induced cystoid macular edema refractory to concomitant intravenous bevacizumab. Can J Ophthalmol. 2011;46:200-1.
45. Meyer KM, Klink T, Ugurel S, Bröcker EB. Regression of paclitaxel-induced maculopathy with oral acetazolamide. Graefes Arch Clin Exp Ophthalmol. 2012;250:463-4.
46. Georgakopoulos CD, Makri OE, Vasilakis P, Exarchou A. Angiographically silent cystoid macular oedema secondary to paclitaxel therapy. Clin Exp Optom. 2012;95:233-6.
47. Kuznetcova TI, Cech P, Herbort CP. The mystery of angiographically silent macular oedema due to taxanes. Int Ophthalmol. 2012;32:299-304.
48. Ham DS, Lee JE, Kim HW, Yun IH. A case of cystoid macular edema associated with paclitaxel chemotherapy. Korean J Ophthalmol. 2012;26:388-90.
49. Rahman HT, Yeh S, Bergstrom CS. Cystoid macular edema without leakage secondary to nab-paclitaxel (abraxane): clinical experience with intravitreal bevacizumab. J Ocul Pharmacol Ther. 2013;29:360-2.
50. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652-62.
51. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep. 1978;62:315-20.
52. McKeown CA, Swartz M, Blom J, Maggiano JM. Tamoxifen retinopathy. Br J Ophthalmol. 1981;65:177-9.
53. Gerner EW. Ocular toxicity of tamoxifen. Ann Ophthalmol. 1989;21:420-3.
54. Griffiths MF. Tamoxifen retinopathy at low dosage. Am J Ophthalmol. 1987;104:185-6.
55. Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, Gomolin JE, Margolese RG, Mathen MK, Bowman DM, Kaufman DI, Dimitrov NV, Singerman LJ, Bornstein R, Wolmark N. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol. 1998;125:493-501.
56. Lazzaroni F, Scorolli L, Pizzoleo CF, Savini G, De Nigris A, Giosa F, Meduri RA. Tamoxifen retinopathy: does it really exist? Graefes Arch Clin Exp Ophthalmol. 1998;236:669-73.
57. Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer. 1992;69:2961-4.
58. Gualino V, Cohen SY, Delyfer MN, Sahel JA, Gaudric A. Optical coherence tomography findings in tamoxifen retinopathy. Am J Ophthalmol. 2005;140:757-8.
59. Bourla DH, Sarraf D, Schwartz SD. Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. Am J Ophthalmol. 2007;144:126-8.
60. Bourla DH, Gonzales CR, Mango CW, Moral JN, Wirthlin RS, Schwartz SD. Intravitreous vascular endothelial growth factor (VEGF) inhibitor therapy for tamoxifen induced macular edema. Semin Ophthalmol. 2007;22:87-8.
61. Park SS, Zawadzki RJ, Truong SN, Choi SS, Werner JS. Microcystoid maculopathy associated with tamoxifen use diagnosed by high-resolution fourier-domain optical coherence tomography. Retin Cases Brief Rep. 2009;3:33-5.
62. Chung SE, Kim SW, Chung HW, Kang SW. Estrogen antagonist and development of macular hole. Korean J Ophthalmol. 2010;24:306-9.
63. Cronin BG, Lekich CK, Bourke RD. Tamoxifen therapy conveys increased risk of developing a macular hole. Int Ophthalmol. 2005;26:101-5.
64. Mäenpää H, Mannerström M, Toimela T, Salminen L, Saransaari P, Tähti H. Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells. Pharmacol Toxicol. 2002;91:116-22.
65. Dyer MA, Cepko CL. Control of Müller glial cell proliferation and activation following retinal injury. Nat Neurosci. 2000;3:873-80.
66. Rahimy E, Sarraf D. Bevacizumab therapy for tamoxifen-induced crystalline retinopathy and severe cystoid macular edema. Arch Ophthalmol. 2012;130:931-2.
67. Mauget-Faÿsse M, Gambrelle J, Quaranta-El Maftouhi M. Optical coherence tomography in tamoxifen retinopathy. Breast Cancer Res Treat. 2006;99:117-8.
68. Gass JD. Nicotinic acid maculopathy. Am J Ophthalmol. 1973;76:500-10.
69. Jampol LM. Niacin maculopathy. Ophthalmology. 1988;95:1704-5.
70. Millay RH, Klein ML, Illingworth DR. Niacin maculopathy. Ophthalmology. 1988;95:930-6.
71. Fraunfelder FW, Fraunfelder FT, Illingworth DR. Adverse ocular effects associated with niacin therapy. Br J Ophthalmol. 1995;79:54-6.
72. Callanan D, Blodi BA, Martin DF. Macular edema associated with nicotinic acid (niacin). JAMA. 1998;3(279):1702.
73. Spirn MJ, Warren FA, Guyer DR, Klancnik JM, Spaide RF. Optical coherence tomography findings in nicotinic acid maculopathy. Am J Ophthalmol. 2003;135:913-4.
74. Dajani HM, Lauer AK. Optical coherence tomography findings in niacin maculopathy. Can J Ophthalmol. 2006;41:197-200.
75. Davis MJ, Ravage ZB, Packo KH, Arevalo JF, Bernstein PS, Berger AS. Diagnostic and therapeutic challenges. Retina. 2008;28:520-4.
76. Deuter CM, Kötter I, Günaydin I, Stübiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906-13.
77. Hayasaka S, Nagaki Y, Matsumoto M, Sato S. Interferon associated retinopathy. Br J Ophthalmol. 1998;82:323-5.
78. Abd El-Badie Mohamed M, Abd-El Azeem Eed K. Retinopathy associated with interferon therapy in patients with hepatitis C virus. Clin Ophthalmol. 2012;6:1341-5.
79. Tokai R, Ikeda T, Miyaura T, Sato K. Interferon-associated retinopathy and cystoid macular oedema. Arch Ophthalmol. 2001;119:1077-9.
80. Shimura M, Saito T, Yasuda K, Tamai M. Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography. Jpn J Ophthalmol. 2005;49:231-4.
81. Sheth HG, Michaelides M, Siriwardena D. Cystoid macular edema and visual loss as sequelae to interferon alpha treatment of systemic hepatitis C. Indian J Ophthalmol. 2010;58:147-8.
82. Kang HY, Shin MC. Pegylated interferon-associated severe retinopathy in a patient with chronic hepatitis. Korean J Ophthalmol. 2012;26:147-50.
83. Nagaoka T, Sato E, Takahashi A, Yokohama S, Yoshida A. Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C. Invest Ophthalmol Vis Sci. 2007;48:368-75.
84. Lalonde RG, Deschênes JG, Seamone C. Zidovudine-induced macular edema. Ann Intern Med. 1991;114:297-8.
85. Vaudaux JD, Guex-Crosier Y. Rifabutin-induced cystoid macular oedema. J Antimicrob Chemother. 2002;49:421-2.
86. Smith WM, Reddy MG, Hutcheson KA, Bishop RJ, Sen HN. Rifabutin-associated hypopyon uveitis and retinal vasculitis with a history of acute myeloid leukemia. J Ophthalmic Inflamm Infect. 2012;2:149-52.
87. Lois N, White M. Acitretin-associated maculopathy. Arch Ophthalmol. 2004;122:928-30.
88. Barak A, Morse LS, Schwab I. Leflunomide (Arava)-induced cystoid macular oedema. Rheumatology (Oxford). 2004;43:246-8.
89. Kusumi E, Arakawa A, Kami M, Kato D, Yuji K, Kishi Y, Murashige N, Miyakoshi S, Ueyama J, Morinaga S, Taniguchi S, Muto Y. Visual disturbance due to retinal edema as a complication of imatinib. Leukemia. 2004;18:1138-9.
90. Masood I, Negi A, Dua HS. Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery. J Cataract Refract Surg. 2005;31:2427-8.
91. Georgalas I, Pavesio C, Ezra E. Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect. Graefes Arch Clin Exp Ophthalmol. 2007;245:1585-6.
92. Magrath GN, Pulido JS, Montero J, Mason C, Wilson J. Cystoid macular edema secondary to fluconazole toxicity. Ocul Immunol Inflamm. 2010;18:472-4.
93. Bussone G, Kaswin G, de Menthon M, Delair E, Brézin AP, Guillevin L. Macular oedema following rituximab infusion in two patients with Wegener's granulomatosis. Clin Exp Rheumatol. 2010;28:90-2.
94. Iacono P, Battaglia Parodi M, Bandello F. Macular edema associated with hydrochlorothiazide therapy. Br J Ophthalmol. 1025;2011(95):1036-7.
95. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103:138-47.
96. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297-304.
97. Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation? Curr Opin Ophthalmol. 2000;11:94-100.
98. Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol. 1997;124:683-5.
99. Thorne JE, Maguire AM, Lanciano R. CME and anterior uveitis with latanoprost use. Ophthalmology. 1998;105:1981-3.
100. Gaddie IB, Bennett DW. Cystoid macular edema associated with the use of latanoprost. J Am Optom Assoc. 1998;69:122-8.
101. Avakian A, Renier SA, Butler PJ. Adverse effects of latanoprost on patients with medically resistant glaucoma. Arch Ophthalmol. 1998;116:679-80.
102. Heier JS, Steinert RF, Frederick AR Jr. Cystoid macular edema associated with latanoprost use. Arch Ophthalmol. 1998;116:680-2.
103. Ayyala RS, Cruz DA, Margo CE, Harman LE, Pautler SE, Misch DM, Mines JA, Richards DW. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol. 1998;126:602-4.
104. Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol. 1998;126:134-5.
105. Wardrop DR, Wishart PK. Latanoprost and cystoid macular oedema in a pseudophake. Br J Ophthalmol. 1998;82:843-4.
106. Weisz JM, Bressler NM, Bressler SB, Schachat AP. Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. Ophthalmology. 1999;106:1656-9.
107. Moroi SE, Gottfredsdottir MS, Schteingart MT, Elner SG, Lee CM, Schertzer RM, Abrams GW, Johnson MW. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology. 1999;106:1024-9.
108. Halpern DL, Pasquale LR. Cystoid macular edema in aphakia and pseudophakia after use of prostaglandin analogs. Semin Ophthalmol. 2002;17:181-6.
109. Tokunaga T, Kashiwagi K, Saito J, Kobayashi K, Kobori Y, Abe K, Tsukahara S. A case of cystoid macular edema associated with latanoprost ophthalmic solution. Jpn J Ophthalmol. 2002;46:656-9.
110. Watanabe K, Hayasaka S, Hayasaka Y, Nagaki Y, Watanabe K. Cystoid macular edema associated with latanoprost use in a pseudophakic eye with a history of surgical complications. Jpn J Ophthalmol. 2003;47:110-2.
111. Jäger M, Jonas JB. Cystoid macular edema associated with latanoprost therapy in a pseudophakic vitrectomized patient after removal of silicone oil endotamponade. Eur J Ophthalmol. 2003;13:221-2.
112. Ahad MA, McKee HD. Stopping prostaglandin analogues in uneventful cataract surgery. J Cataract Refract Surg. 2004;30:2644-5.
113. Altintaş O, Yüksel N, Karabaş VL, Demirci G. Cystoid macular edema associated with latanoprost after uncomplicated cataract surgery. Eur J Ophthalmol. 2005;15:158-61.
114. Dhingra N, Morgan JE. Pseudophakic cystoid macular oedema: 30 months after latanoprost challenge. Eye (Lond). 2007;21:269-71.
115. Ozdemir H, Karacorlu M, Karacorlu SA. Serous detachment of macula in cystoid macular edema associated with latanoprost. Eur J Ophthalmol. 2008;18:1014-6.
116. Grigoropoulos VG, Emfietzoglou I, Nikolaidis P, Theodossiadis PG, Theodossiadis GP. Cystoid macular oedema within 24 h after a single application of latanoprost. Int Ophthalmol. 2009;29:257-9.
117. Panteleontidis V, Detorakis ET, Pallikaris IG, Tsilimbaris MK. Latanoprost-dependent cystoid macular edema following uncomplicated cataract surgery in pseudoexfoliative eyes. Ophthalmic Surg Lasers Imaging. 2010;9:1-5.
118. Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002;47:S219.
119. Wand M, Gaudio AR. Cystoid macular edema associated with ocular hypotensive lipids. Am J Ophthalmol. 2002;133:403-5.
120. Esquenazi S. Cystoid macular edema in a pseudophakic patient after switching from latanoprost to BAK-free travoprost. J Ocul Pharmacol Ther. 2007;23:567-70.
121. Agange N, Mosaed S. Prostaglandin-induced cystoid macular edema following routine cataract extraction. J Ophthalmol. 2010;2010:690707.
122. Matsuura K, Sasaki S, Uotani R. Successful treatment of prostaglandin-induced cystoid macular edema with subtenon triamcinolone. Clin Ophthalmol. 2012;6:2105-8.
123. Carrillo MM, Nicolela MT. Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost. Am J Ophthalmol. 2004;137:966-8.
124. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105:263-8.
125. Hoyng PF, Rulo AH, Greve EL, Astin M, Gjötterberg M. Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: a review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv Ophthalmol. 1997;41:S83-8.
126. Furuichi M, Chiba T, Abe K, Kogure S, Iijima H, Tsukahara S, Kashiwagi K. Cystoid macular edema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier. J Glaucoma. 2001;10:233-6.
127. Miyake K, Ota I, Maekubo K, Ichihashi S, Miyake S. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol. 1999;117:34-40.
128. Lima MC, Paranhos A Jr, Salim S, Honkanen R, Devgan L, Wand M, Gaudio AR, Shields MB. Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost. J Glaucoma. 2000;9:317-21.
129. Wand M, Gaudio AR, Shields MB. Latanoprost and cystoid macular edema in high-risk aphakic or pseudophakic eyes. J Cataract Refract Surg. 2001;27:1397-401.
130. Costagliola C, Del Prete A, Verolino M, Antinozzi P, Fusco R, Parmeggiani F, Mastropasqua L. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients. Graefes Arch Clin Exp Ophthalmol. 2002;240:379-86.
131. Arcieri ES, Santana A, Rocha FN, Guapo GL, Costa VP. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005;123:186-92.
132. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53:S93-105.
133. Wand M, Shields BM. Cystoid macular edema in the era of ocular hypotensive lipids. Am J Ophthalmol. 2002;133:393-7.
134. Mataftsi A, Tsaousis KT, Tsinopoulos IT, Dimitrakos SA. Survey of perioperative prostaglandin analogue administration during cataract surgery in Greece. Int Ophthalmol. 2012;32:97-8.
135. Kolker AE, Becker B. Epinephrine maculopathy. Arch Ophthalmol. 1968;79:552-62.
136. Michels RG, Maumenee AE. Cystoid macular edema associated with topically applied epinephrine in aphakic eyes. Am J Ophthalmol. 1975;80:379-88.
137. Mackool RJ, Muldoon T, Fortier A, Nelson D. Epinephrine-induced cystoid macular edema in aphakic eyes. Arch Ophthalmol. 1977;95:791-3.
138. Obstbaum SA, Galin MA, Poole TA. Topical epinephrine and cystoid macular edema. Ann Ophthalmol. 1976;8:455-8.
139. Thomas JV, Gragoudas ES, Blair NP, Lapus JV. Correlation of epinephrine use and macular edema in aphakic glaucomatous eyes. Arch Ophthalmol. 1978;96:625-8.
140. Mehelas TJ, Kollarits CR, Martin WG. Cystoid macular edema presumably induced by dipivefrin hydrochloride (Propine). Am J Ophthalmol. 1982;94:682.
141. Miyake K, Shirasawa E, Hikita M. Active transport system of prostaglandins: clinical implications and considerations. J Cataract Refract Surg. 1992;18:100-5.
142. Miyake K, Kayazawa F, Manabe R, Miyake Y. Indomethacin and the epinephrine-induced breakdown of the blood-ocular barrier in rabbits. Invest Ophthalmol Vis Sci. 1987;28:482-6.
143. Bozkurt E, Yazici AT, Pekel G, Albayrak S, Cakir M, Pekel E, Yilmaz OF. Effect of intracameral epinephrine use on macular thickness after uneventful phacoemulsification. J Cataract Refract Surg. 2010;36:1380-4.
144. Hesse RJ, Swan JL 2nd. Aphakic cystoid macular edema secondary to betaxolol therapy. Ophthalmic Surg. 1988;19:562-4.
145. Miyake K, Ota I, Ibaraki N, Akura J, Ichihashi S, Shibuya Y, Maekubo K, Miyake S. Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol. 2001;119:387-94.
146. Miyake K, Ibaraki N, Goto Y, Oogiya S, Ishigaki J, Ota I, Miyake S. ESCRS Binkhorst lecture 2002: pseudophakic preservative maculopathy. J Cataract Refract Surg. 2003;29:1800-10.